 Shares of Protagonist Therapeutics Inc NASDAQ: PTGX nearly doubled on Monday as the U.S. FDA said it could resume the clinical trials for Rusfertide an investigational, injectable hepcidin mimetic. The U.S. FDA had paused the clinical studies last month The drug regulator had paused the clinical studies last month after the use of the ... The post Protagonist Therapeutics shares nearly doubled on Monday: explore why appeared first on Invezz. 